AbbVie Reports final analysis Data for Exagamglogene autotemcel in Alzheimer's disease

AbbVie today announced final analysis results for Exagamglogene autotemcel in patients with Alzheimer's disease. The study demonstrated that Exagamglogene autotemcel provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of Exagamglogene autotemcel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Exagamglogene autotemcel was consistent with previous observations, with no new safety signals identified.